CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 660 enrolled
Drug / intervention
Nitric Oxide Gasdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05721144
NCT05721144Phase 2Completed

Inhaled NO ReDuce postoperatIve pulmoNAry complicATions in patiEnts With Recent COVID-19 Infection

Xijing Hospital·interventional·Posted Feb 9, 2023·Updated May 10, 2024

In Brief

A Phase 2 clinical trial evaluating Nitric Oxide Gas for Nitric Oxide and 3 related conditions. Completed, enrolled 660 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the effect of perioperative inhalation of NO on reducing the incidence of postoperative pulmonary complications in patients with recent COVID-19 infection, and to evaluate whether inhaled NO can improve the prognosis of patients. The investigators will enroll 660 surgical patients who was infected with SARS-CoV-2 within 42days (7 weeks ) prior to planed surgery under general anesthesia. Patients will be randomized to receive either inhaled nitric oxide (per protocol) or a placebo. Perioperative standards of care will be the institution's own protocols (such as ventilation strategies and use and dose of anesthetics, analgesia and fluid management, etc).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedFeb 9, 2023
Enrollment StartFeb 17, 2023
Primary CompletionApr 14, 2024
Study CompletionMay 7, 2024
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 3.4 years ago

Interventions

Nitric Oxide Gasdrug

Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.